Cargando…
DPP-4 Inhibition and the Path to Clinical Proof
In the 1990s it was discovered that the enzyme dipeptidyl peptidase-4 (DPP-4) inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). DPP-4 inhibition results in raised levels of the two incretin hormones which in turn result in lower...
Autor principal: | Ahrén, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593050/ https://www.ncbi.nlm.nih.gov/pubmed/31275243 http://dx.doi.org/10.3389/fendo.2019.00376 |
Ejemplares similares
-
DPP‐4 inhibition and islet function
por: Ahrén, Bo
Publicado: (2011) -
Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019) -
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
por: Ahrén, Bo
Publicado: (2008) -
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010) -
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
por: Deacon, Carolyn F.
Publicado: (2019)